Applications of immune checkpoint inhibitors (ICIs), especially those targeting CTLA-4 (cytotoxic T-lymphocyte associated protein 4) and PD-1/PD-L1 (programmed cell death protein 1/programmed cell death ligand 1), have revolutionized the treatment of various aggressive cancers [1]. This evidence concerns the gene CTLA4 and cancer.